Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate in advanced bladder cancer

A G Turner

    Cancer Treatment Reports
    |January 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Methotrexate chemotherapy demonstrated significant response rates in advanced bladder cancer patients. Two of three regimens showed over 50% efficacy, with better outcomes for metastatic disease.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer.

    Oncogene·2017
    Same author

    Differential effects of 1,25-dihydroxyvitamin D on mineralisation and differentiation in two different types of osteoblast-like cultures.

    The Journal of steroid biochemistry and molecular biology·2012
    Same author

    Regulation of the 5'-flanking region of the human CYP27B1 gene in osteoblast cells.

    Molecular and cellular endocrinology·2009
    Same author

    Laparoscopic port-site metastases from bladder transitional cell carcinoma.

    BJU international·2009
    Same author

    Emu oil(s): a source of non-toxic transdermal anti-inflammatory agents in aboriginal medicine.

    Inflammopharmacology·2007
    Same author

    Incidence of Helicobacter pylori in patients with interstitial cystitis.

    European urology·2002
    Same journal

    Rhabdomyolysis associated with high-dose cytarabine.

    Cancer treatment reports·1987
    Same journal

    Acute laryngeal edema after single-dose irradiation and doxorubicin.

    Cancer treatment reports·1987
    Same journal

    Timing may be a critical factor in drug therapy.

    Cancer treatment reports·1987
    Same journal

    Prednimustine in advanced malignant melanoma: a phase II study.

    Cancer treatment reports·1987
    Same journal

    Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    Same journal

    Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Advanced bladder cancer presents a significant clinical challenge.
    • Methotrexate is a chemotherapy agent with established use in various cancers.

    Purpose of the Study:

    • To evaluate the efficacy and toxicity of different methotrexate regimens in patients with advanced bladder cancer.
    • To compare response rates between locally advanced and metastatic disease.

    Main Methods:

    • A retrospective study of 64 patients with advanced local or metastatic bladder cancer treated between 1970 and 1979.
    • Administration of methotrexate via three distinct treatment regimens.
    • Assessment of treatment response and toxicity based on clinical outcomes and renal function.

    Main Results:

    Related Experiment Videos

    • Two of the three studied methotrexate regimens achieved response rates exceeding 50%.
    • The overall response rate for metastatic bladder cancer was 44%, compared to 16% for locally advanced disease.
    • Toxicity was generally minimal, contingent upon satisfactory renal function.

    Conclusions:

    • Methotrexate is an effective treatment option for advanced bladder cancer, with specific regimens showing high response rates.
    • Metastatic disease exhibited a higher response rate to methotrexate compared to locally advanced disease.
    • Careful monitoring of renal function is crucial to minimize methotrexate-related toxicity.